Dhiren Patel
Vice President - Clinical Development Actinium Pharmaceuticals
Dhiren Patel is the Vice President of Clinical Development at Actinium Pharmaceuticals, with a career spanning over a decade in oncology drug development. He has led programs across radioligand therapy, antibody-drug conjugates, and immuno-oncology, guiding projects from early-phase studies through global regulatory approval. Dhiren operates at the intersection of clinical science, business strategy, and patient care, building and shaping teams while engaging partners to accelerate therapeutic development. His work is focused on advancing the next generation of precision oncology therapies, driving innovations that aim to redefine the future of cancer care.
Seminars
Wednesday 22nd July 2026
De-Risking First-in-Human PSMA Radioligand Therapy by Translating Terbium-161 Biology, Dosimetry, & Safety into Early-Phase Dose Decisions
2:00 pm
- Exploring whether dual beta–Auger emissions can control tumors effectively without surprising early side effects
- Finding safe and scalable dose levels that turn promising microdosimetry into confident first-in-human decisions
- Gathering early clinical signals to guide go/ no-go decisions before larger, resource-heavy trials
